Will BeyondSpring stock go up?

According to Danelfin AI, BeyondSpring has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (45.22%) is -5.59% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for BeyondSpring stock?

The BeyondSpring target price is $1.38 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold BeyondSpring stock right now?

BeyondSpring has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (45.22%) is -5.59% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether BeyondSpring stock is a good buy .

Is BeyondSpring undervalued right now?

Based on analysts, the average price target downside for BeyondSpring is -26.04% (1Y). According to Danelfin AI, BeyondSpring has today an AI Score of 3/10 (Sell Rating).

What was the price range of BeyondSpring stock over the past 12 months?

The BeyondSpring stock price range over the past 12 months has been $1.27 - $3.17.

What is going on with BeyondSpring stock in the last 3 months?

The BeyondSpring stock performance in the last quarter has been +14.02%.

Does BeyondSpring offer dividend payments?

No, BeyondSpring does not currently pay dividends.

What is the current market capitalization of BeyondSpring?

BeyondSpring's market cap is $76.07M, as of 2026-07-02 08:00.

When is the next BYSI earnings report date?

BYSI will publish its next earnings report on 2026-03-25.

Beyondspring Inc (BYSI) AI Stock Analysis

Advanced Chart

Custom range

Jul 2, 2025

→

Jul 2, 2026

Custom range

Jul 2, 2025

→

Jul 2, 2026

BYSI AI-Powered Stock Analysis

AI Score Explanation

AI Score

Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Beyondspring Inc today receives an AI Score of 3/10, which translates to a Sell rating. The stock has a 45% probability of outperforming the market in the next 3 months, which is 6% lower than the average probability of any stock (51%). The top positive contributor is the aggregated impact of technical indicators not individually reported (Technicals Impact Long Tail), which adds +2.67% to the probability. Other positive signals include low 90-day volatility (ATR, bottom 10%) boosting probability by +0.84%, low average volume (bottom 10%) adding +0.53%, a favorable 60-day chart pattern adding +0.48%, and a low 1-year alpha (bottom 30%) adding +0.48%. On the negative side, the strongest detractors are the analyst mean price target upside (bottom 10%) reducing probability by -1.47%, the distance from the 20-day KAMA (top 10%) reducing by -1.17%, and the 180-day chart pattern reducing by -1.17%. The Fear & Greed Index (value 31, indicating fear) also detracts by -1.06%, while low beginning cash (bottom 20%), low institutional ownership (bottom 20%), and negative tangible shareholders' equity (bottom 20%) each reduce probability by around -0.8% to -0.4%. Notable data points include the stock's low institutional ownership of 5.31% (bottom 20%), which typically signals lower confidence from large investors. The analyst mean price target upside is negative at -31.8% (bottom 10%), indicating analysts expect the stock to decline. The stock also has negative tangible shareholders' equity of -$30.35 million (bottom 20%) and negative total common equity (bottom 10%), reflecting weak financial health. On the positive side, the stock's low volatility (ATR bottom 10%) and low average volume (bottom 10%) may appeal to risk-averse investors, but these are outweighed by the many negative signals. Overall, the combination of poor fundamentals, negative analyst sentiment, and bearish technical patterns leads to a low AI Score and a Sell rating, suggesting the stock is more likely to underperform the market over the next three months.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Volatility+0.75%
How much the stock price tends to fluctuate
Earnings Quality+0.24%
Stability and reliability of reported earnings

Sentiment-3.68%
How analysts and the market view the stock
Momentum-1.14%
Direction and strength of recent price movements
Valuation-1.02%
How the stock is priced relative to its fundamentals
Financial Strength-0.41%
Balance sheet strength and financial resilience
Size & Liquidity-0.33%
Company size and trading liquidity

BYSI probability advantage of beating the market (3M):

-5.59%

AI Score

Sell

BeyondSpring (BYSI) has an AI Score of 3/10 (Sell) because, according to an overall analysis, it has a probability advantage of -5.59% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of BYSI (45.22%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
BYSI probability advantage of beating the market (3M)-5.59%
BYSI probability of beating the market (3M)45.22%

BYSI probability advantage of beating the market (3M): -5.59%

The AI-powered overall analysis of BeyondSpring (BYSI) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of BYSI:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Technical	Technicals Impact (Long Tail)	-	N/A	+2.67%
Sentiment	Analyst Mean Price Target Upside	-0.32%	N/A	-1.47%
Technical	Distance from KAMA (20d)	0.17%		-1.17%
Technical	Chart Pattern (180d)	figure_157	N/A	-1.17%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.06%
Fundamental	Beginning Cash (Millions)	7.79		-0.86%
Sentiment	Institutional Ownership	5.31%		-0.84%
Technical	ATR (90d Volatility)	0.14	N/A	+0.84%
Technical	Chart Pattern (120d)	figure_45	N/A	-0.75%
Technical	Chart Pattern (252d)	figure_16	N/A	-0.61%
Technical	Upgrade to unlock			+0.53%
Technical	Upgrade to unlock			-0.50%
Technical	Upgrade to unlock			+0.48%
Technical	Upgrade to unlock			+0.48%
Fundamental	Upgrade to unlock			-0.42%

Rest of Alpha Signals: -1.76%

BYSI probability advantage of beating the market (3M)Total:-5.59%
BYSI AI Score

Significant changes Vs previous day

BYSI Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$1.87
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

BYSI Proven Sell Signal & Price Forecast

This is the price chart for BYSI from January 1, 2026 until today. The chart indicates, in red, the 74 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

BYSI Average Past Performance & Loss Rate

Three months after its 882 Sell signals since July 2026, BYSI had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

882 Past BYSI Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-27.50%
Average Alpha				-38.07%
Loss Rate (% Negative Perf.)				87.56%
% Negative Alpha				90.26%

BYSI Frequently Asked Questions

Will BeyondSpring stock go up?
According to Danelfin AI, BeyondSpring has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (45.22%) is -5.59% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for BeyondSpring stock?
Is it a good time to buy, sell, or hold BeyondSpring stock right now?
Is BeyondSpring undervalued right now?
What was the price range of BeyondSpring stock over the past 12 months?
What is going on with BeyondSpring stock in the last 3 months?
Does BeyondSpring offer dividend payments?
What is the current market capitalization of BeyondSpring?
When is the next BYSI earnings report date?

Beyondspring Inc Company Profile

BeyondSpring Inc. operates as a clinical stage biopharmaceutical entity, jointly with its subsidiary companies. Primarily concentrated on innovating cancer treatment therapies, the company's principal resource is Plinabulin - a distinctly aimed immune-altering microtubule-binding agent. This vital asset has successfully completed Phase III clinical trials in terms of mitigating chemotherapy-induced neutropenia and treating later stages of non-small cell lung cancer.

Moreover, BeyondSpring Inc is committed to advancing Plinabulin combined with an array of immuno-oncology substances. Among these are nivolumab - a PD-1 antibody used for treating non-small cell lung cancer and ipilimumab - a CTLA-4 antibody employed in dealing with extensive-stage small cell lung cancer. Moreover, the company employs Plinabulin in conjunction with either PD-1 or PD-L1 antibodies as well as radiation for managing various forms of cancers.

In addition to this, the company takes an active part in creating three preclinical stage small molecule immune agents along with a drug development platform. BeyondSpring Inc was founded back in 2010 and has established its headquarters in New York City.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:100 Campus Drive, West Side, 4Th Floor, Suite 410, Florham Park
Employees:44
Website:beyondspringpharma.com

Pros

Proprietary drug candidate intellectual property protection

Addressing high unmet medical needs in oncology

Potential for platform technology leverage across indications

Global market access strategy for future commercialization

High potential for future licensing and partnership agreements

Cons

Extremely high capital intensity of drug development

Company	AI Score	Compare
BOLDBoundless Bio Inc

Company	AI Score	Compare
BOLDBoundless Bio Inc

BYSI Stock AI Analysis